Keidanren Calls for Review of Japan's Unique Pharmaceutical Regulations
To read the full story
ORGANIZATION
- Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
January 29, 2025
- JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
January 24, 2025
- Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
January 17, 2025
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…